Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

The SUMOylation inhibitor subasumstat potentiates rituximab activity by IFN1-dependent macrophage and NK cell stimulation

Akito Nakamura, Stephen Grossman, Keli Song, Kristina Xega, Yuhong Zhang, Donna Cvet, Allison Berger, Gary Shapiro, Dennis Huszar

Blood (2022) 139 (18): 2770–2781.

https://doi.org/10.1182/blood.2021014267

Published: 2022

Includes: Supplemental data

Journal Articles

Targeting Hypersumoylation in Mantle Cell Lymphoma

Walter Hanel, MD PhD, Liudmyla Tsyba, PhD, Dennis Huszar, PhD, Alex Prouty, Xiaoli Zhang, PhD, JoBeth Helmig-Mason, Msc, Bethany L Mundy-Bosse, PhD, Youssef Youssef, MD, Samir Parekh, MD, Kami J. Maddocks, MD, Robert A Baiocchi, MD PhD, Lapo Alinari, MD PhD

Blood (2019) 134 (Supplement_1): 4060.

https://doi.org/10.1182/blood-2019-127363

Published: 2019

Journal Articles

A Phase 1b/2 Study of TAK-981, a First-in-Class Sumoylation Inhibitor, in Combination with Rituximab in Patients with Relapsed/Refractory (r/r) CD20-Positive Non-Hodgkin Lymphoma (NHL)

Sarit Assouline, MD, Amitkumar Mehta, MD, Paolo F Caimi, MD, Bingxia Wang, PhD, Chirag Patel, Mi-Sook Kim, Dennis Huszar, Allison J Berger, PhD, Sharon Friedlander, Alejandro Gomez-Pinillos, Igor Proscurshim

Blood (2019) 134 (Supplement_1): 1593.

https://doi.org/10.1182/blood-2019-128773

Published: 2019

Journal Articles

Pharmacologic Inhibition of SUMO-Activating Enzyme (SAE) with TAK-981 Augments Interferon Signaling and Regulates T Cell Differentiation in Ex Vivo studies of Chronic Lymphocytic Leukemia (CLL)

Vi Lam, Scott R Best, BS, Nur Bruss, BS, Tingting Liu, Taylor Hashiguchi Rowland, BS, Dennis Huszar, PhD, Alexey Danilov, MD PhD

Blood (2019) 134 (Supplement_1): 1760.

https://doi.org/10.1182/blood-2019-127539

Published: 2019

Journal Articles

Concurrent Inhibition of Pim-1 and FLT3 Kinases in FLT3-ITD Acute Myeloid Leukemia Post-Translationally Downregulates the Anti-Apoptotic Protein Mcl-1 through Downregulation of the Mcl-1 Deubiquitinase USP9X

Patrick R. Baldwin, PhD, Shivani Kapoor, B.S., Karthika Natarajan, PhD, Rossana Trotta, PhD, Adriana Tron, PhD, Dennis Huszar, PhD, Eduardo Davila, PhD, Danilo Perrotti, MD PhD, Maria R. Baer, MD

Blood (2016) 128 (22): 35.

https://doi.org/10.1182/blood.V128.22.35.35

Published: 2016

Journal Articles

The Pim Kinase Inhibitor AZD1208 Enhances Topoisomerase-2 Inhibitor Induction of Apoptosis of Acute Myeloid Leukemia Cells with FLT3-ITD through Increased Oxidative Stress

Kshama A. Doshi, M.S., Karthika Natarajan, PhD, Feyruz V. Rassool, PhD, Dennis Huszar, PhD, Maria R. Baer, MD

Blood (2015) 126 (23): 1268.

https://doi.org/10.1182/blood.V126.23.1268.1268

Published: 2015

Journal Articles

The Biologic Relevance of PIM Kinases in the Context of Multiple Myeloma and Their Potential As Therapeutic Targets in Combination Drug Therapy

Janani Ramachandran, MA, Loredana Santo, MD, Homare Eda, MDPhD, Dharminder Chauhan, PhD, Ka Tat Siu, PhD, Miroslav Koulnis, PhD, Dennis Huszar, PhD, Kenneth C Anderson, MD, Noopur S. Raje, MD

Blood (2015) 126 (23): 2992.

https://doi.org/10.1182/blood.V126.23.2992.2992

Published: 2015

Journal Articles

Preclinical and Clinical Pharmacodynamics of Pan-Pim Inhibition By AZD1208 in Acute Myeloid Leukemia: Assessment of Pim Isoform Dependency for Bad and 4EBP1 Phosphorylation

Kristen A McEachern, PhD, Adriana E Tron, PhD, Greg O'Connor, Rachel DuPont, Francis D Gibbons, PhD, Lourdes Pablo, Karthick Vishwanathan, PhD, Patricia McCoon, PhD, Jorge E. Cortes, MD, Daniel J. DeAngelo, MDPhD, Mark D Minden, MDPhD, Geoffrey L. Uy, MD, Frank Neumann, MDPhD, Karen Keating, Dennis Huszar, PhD, J. Elizabeth Pease, PhD, Jeffrey Brown, PhD, J. Carl Barrett, PhD

Blood (2014) 124 (21): 906.

https://doi.org/10.1182/blood.V124.21.906.906

Published: 2014

Journal Articles

Synergistic Induction of Cell Death By Combined Inhibition of PIM and AKT Kinases in Cytogenetically Defined Standard and High-Risk Multiple Myeloma

Koremu Meja, Dean Smith, MBBS, Laura Percy, Dennis Huszar, PhD, Barry R Davies, Kwee L Yong, MBChB, PhD, Asim Khwaja

Blood (2014) 124 (21): 4723.

https://doi.org/10.1182/blood.V124.21.4723.4723

Published: 2014

Journal Articles

Effect of the Pan-PIM Kinase Inhibitor, AZD1208, Alone and in Combination with Bortezomib in Multiple Myeloma

Loredana Santo, Janani Ramachandran, Diana D Cirstea, Homare Eda, Neeharika Nemani, Teru Hideshima, Chauhan Dharminder, Dennis Huszar, PhD, Kenneth C. Anderson, MD, Noopur Raje, MD

Blood (2014) 124 (21): 5726.

https://doi.org/10.1182/blood.V124.21.5726.5726

Published: 2014

Journal Articles

The Pim Kinase Inhibitor AZD1208 Enhances Apoptosis Induction By Clinically Active FLT3 Inhibitors in FLT3-ITD Acute Myeloid Leukemia Cells in Vitro and in Vivo through Synergistic Downregulation of Mcl-1 and of Bcl-xL

Karthika Natarajan, PhD, Trevor J Mathias, MS, Kshama A Doshi, MS, Adriana E Tron, PhD, Manfred Kraus, PhD, Rossana Trotta, PhD, Danilo Perrotti, MD PhD, Dennis Huszar, PhD, Maria R Baer, MD

Blood (2014) 124 (21): 3601.

https://doi.org/10.1182/blood.V124.21.3601.3601

Published: 2014

Journal Articles

AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia

Blood (2014) 123 (6): 905–913.

https://doi.org/10.1182/blood-2013-04-495366

Published: 2014

Includes: Supplemental data

Journal Articles

AZD1208, a Novel, Potent and Selective Pan PIM Kinase Inhibitor, Demonstrates Efficacy in Models of Acute Myeloid Leukemia

Erika Keeton, Ph.D., Sangeetha Palakurthi, Ph.D., Marat Alimzhanov, Ph.D., Michael Grondine, Yuching Chen, Jeffrey Brown, Ph.D, Kristen McEachern, Ph.D., Yichen Cao, Dharmaraj Chinnappan, Minhui Shen, Les Dakin, Ph.D., Xiao Zheng, Michelle Lamb, Ph.D., Allan Wu, Huawei Chen, Ph.D., Paul Lyne, Ph.D., Dennis Huszar, Ph.D.

Blood (2011) 118 (21): 1540.

https://doi.org/10.1182/blood.V118.21.1540.1540

Published: 2011

Journal Articles

Effects of a Novel, Selective Jak2 Inhibitor, AZ60, on STAT5 Signaling and Cellular Growth in Jak2 V617F Cell Lines.

Joseph M. Gozgit, PhD, Geraldine A. Bebernitz, BS, Pankaj Patil, MS, Minwei Ye, MS, Jiaquan Wu, PhD, Stephanos Ioannidis, PhD, Audrey Davies, BS, Tao Wang, PhD, Dennis Huszar, PhD, Michael Zinda, PhD

Blood (2007) 110 (11): 3549.

https://doi.org/10.1182/blood.V110.11.3549.3549

Published: 2007

Journal Articles

A Selective and Potent Oral Inhibitor of the JAK2 Tyrosine Kinase Reverses Polycythemia and Leukocytosis Induced by JAK2 V617F in a Mouse Model.

Virginia M. Zaleskas, MD, Wayne W. Chan, BS, Peter Evangelista, BS, Katherine Lazarides, BS, Rajesh Chopra, MD, Michael Zinda, PhD, Dennis Huszar, PhD, Richard A. Van Etten, MD PhD

Blood (2007) 110 (11): 557.

https://doi.org/10.1182/blood.V110.11.557.557

Published: 2007

NARROW

The SUMOylation inhibitor subasumstat potentiates rituximab activity by IFN1-dependent macrophage and NK cell stimulation

Targeting Hypersumoylation in Mantle Cell Lymphoma

A Phase 1b/2 Study of TAK-981, a First-in-Class Sumoylation Inhibitor, in Combination with Rituximab in Patients with Relapsed/Refractory (r/r) CD20-Positive Non-Hodgkin Lymphoma (NHL)

Pharmacologic Inhibition of SUMO-Activating Enzyme (SAE) with TAK-981 Augments Interferon Signaling and Regulates T Cell Differentiation in Ex Vivo studies of Chronic Lymphocytic Leukemia (CLL)

Concurrent Inhibition of Pim-1 and FLT3 Kinases in FLT3-ITD Acute Myeloid Leukemia Post-Translationally Downregulates the Anti-Apoptotic Protein Mcl-1 through Downregulation of the Mcl-1 Deubiquitinase USP9X

The Pim Kinase Inhibitor AZD1208 Enhances Topoisomerase-2 Inhibitor Induction of Apoptosis of Acute Myeloid Leukemia Cells with FLT3-ITD through Increased Oxidative Stress

The Biologic Relevance of PIM Kinases in the Context of Multiple Myeloma and Their Potential As Therapeutic Targets in Combination Drug Therapy

Preclinical and Clinical Pharmacodynamics of Pan-Pim Inhibition By AZD1208 in Acute Myeloid Leukemia: Assessment of Pim Isoform Dependency for Bad and 4EBP1 Phosphorylation

Synergistic Induction of Cell Death By Combined Inhibition of PIM and AKT Kinases in Cytogenetically Defined Standard and High-Risk Multiple Myeloma

Effect of the Pan-PIM Kinase Inhibitor, AZD1208, Alone and in Combination with Bortezomib in Multiple Myeloma

The Pim Kinase Inhibitor AZD1208 Enhances Apoptosis Induction By Clinically Active FLT3 Inhibitors in FLT3-ITD Acute Myeloid Leukemia Cells in Vitro and in Vivo through Synergistic Downregulation of Mcl-1 and of Bcl-xL

AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia

AZD1208, a Novel, Potent and Selective Pan PIM Kinase Inhibitor, Demonstrates Efficacy in Models of Acute Myeloid Leukemia

Effects of a Novel, Selective Jak2 Inhibitor, AZ60, on STAT5 Signaling and Cellular Growth in Jak2 V617F Cell Lines.

A Selective and Potent Oral Inhibitor of the JAK2 Tyrosine Kinase Reverses Polycythemia and Leukocytosis Induced by JAK2 V617F in a Mouse Model.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only